ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prognostic factors"

  • Abstract Number: 0722 • ACR Convergence 2024

    Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis

    Andrea Hinojosa-Azaola1, Marlon Sandino-Bermúdez2, Ana Sarahí Mulia-Soto3, Juan M. Mejía-Vilet4 and Eduardo Martin Nares5, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, 4Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 5Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: Anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) encompass a group of systemic inflammatory diseases with multi-organ involvement. Relapses occur in 14-44% of patients within 18-36 months…
  • Abstract Number: 2048 • ACR Convergence 2024

    Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study

    Maximilian Gysan1, Svitlana Pochepnia2, Helmut Prosch2, Antje Lehmann1, Silvia Lee1, Andreas Renner1, Daniela Gompelmann3, Marco Idzko1, Iris Aykara4, Karolina Anderle4, Peter Weber4, Hans Kiener4, Michael Bonelli4, Daniel Mrak4, Daniel Aletaha5, Helga Lechner-Radner4 and Kastriot Kastrati4, 1Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 2Division of General and Paediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 3Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria., Vienna, Austria, 4Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 5Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria

    Background/Purpose: The prognostic value of bronchoalveolar lavage (BAL) in connective tissue disease-related interstitial lung disease (CTD-ILD) is currently underexplored, resulting in a lack of understanding…
  • Abstract Number: 2558 • ACR Convergence 2024

    Development of Non-genetic Risk Stratification Model of Severe Allopurinol Hypersensitivity Syndrome, a Multicenter Study in Thailand

    Patapong Towiwat1, Wichittra Tassaneeyakul2, Suppachai Lawanaskol3, Chonlaphat Sukasem4, Nontaya Nakkam2, Ticha Rerkpattanapipat4, Jettanong Klaewsongkram5, Pawinee Rerknimitr5, Duangkamon Poolpun6, Worawit Louthrenoo7 and Niwat Saksit8, 1Naresuan university, Phitsanulok, Thailand, 2Khon Kaen university, Khon Kaen, Thailand, 3Chaiprakan hospital, Chiang Mai, Thailand, 4Mahidol university, Bangkok, Thailand, 5Chulalongkorn university, Bangkok, Thailand, 6Buddhachinaraj hospital, Phitsanulok, Thailand, 7Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, 8Phayao university, Phayao, Thailand

    Background/Purpose: Severe allopurinol hypersensitivity (SAH), although uncommon, is a serious adverse event of allopurinol.  Both genetic (HLA-B*58:01) and non-genetic factors (female gender, age ≥60-65 years,…
  • Abstract Number: 0738 • ACR Convergence 2024

    Quantitative Vascular US Has Additional Diagnostic and Prognostic Value in GCA

    Colm Kirby1, Rachael Flood1, Sharon Cowley2, Emma Finlay3, Ronan Mullan1, Grainne Murphy4 and David Kane5, 1Tallaght University Hospital, DUBLIN, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3School of Biotechnology, Dublin City University, Dublin, Ireland, 4Cork University Hospital, Cork, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland

    Background/Purpose: Vascular Ultrasound (VUS) performs well in diagnosing Giant Cell Arteritis (GCA) but its role in monitoring disease activity and in predicting outcomes is unknown…
  • Abstract Number: 2083 • ACR Convergence 2024

    A Novel Scoring System to Predict a Cancer Development in Patients with Idiopathic Inflammatory Myopathy

    Yun Kyu Kim1, Ju yeon Kim2, Jung Yoon Pyo3, Min Jung Kim4, Jin Kyun Park5, Eun Young Lee6, Yun Jong lee3, eun Bong Lee1 and Jun Won park2, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul National University Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 3Seoul National University Bundang Hospital, Seongnam-si, 4Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, 5Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, 63Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Previous studies have demonstrated that idiopathic inflammatory myopathy (IIM) is associated with an elevated cancer risk. However, there is limited evidence on the specific…
  • Abstract Number: 2561 • ACR Convergence 2024

    Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women

    Natalie McCormick1, Amit Joshi2, Robert Terkeltaub3, Tony Merriman4, Matthew Nayor5, Chio Yokose6 and Hyon K. Choi7, 1Massachusetts General Hospital, Boston, MA, 2Channing Division of Network Medicine, Boston, MA, 3Retired, San Diego, CA, 4University of Alabama at Birmingham, Homewood, AL, 5Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 6Massachusetts General Hospital, Waltham, MA, 7Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout.  A previous cross-sectional study of pre-existing gout (n=330…
  • Abstract Number: 0755 • ACR Convergence 2024

    Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica

    Anisha Dua1, Andrea Rubbert-Roth2, Kerri Ford3, Stefano Fiore4, Lita Araujo3, Timothy Beukelman5, Fenglong Xie6 and Jeffrey Curtis7, 1Northwestern University Division of Rheumatology, Chicago, IL, 2Cantonal Hospital St Gallen, St Gallen, Switzerland, 3Sanofi, Cambridge, MA, 4Sanofi, Bridgewater, NJ, 5Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 6University of Alabama at Birmingham, Birmingham, AL, 7The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Polymyalgia rheumatica (PMR), a common inflammatory rheumatic condition in people aged ≥50 years, is primarily treated with glucocorticoids (GC). Extended GC therapy can increase…
  • Abstract Number: 2099 • ACR Convergence 2024

    A Longitudinal Study of Infrapatellar Fat Pad Morphologies as Predictive Markersin Knee Osteoarthritis

    Jean-Pierre Pelletier1, Patrice Paiement1, François Abram2, Marc Dorais3 and Johanne Martel-Pelletier1, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 2Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC, Canada, 3StatSciences Inc., Notre-Dame de l'Île-Perrot, QC, Canada

    Background/Purpose: Currently, no established marker effectively stratifies knee osteoarthritis (OA) patients into subgroups. The infrapatellar fat pad (IPFP) has been proposed as a potential key…
  • Abstract Number: 2624 • ACR Convergence 2024

    Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

    Jessica Neely1, Peter Shrader2, Stacey Tarvin3, Kaveh Ardalan4, Susan Shenoi5, Adam Huber6, Susan Kim7 and Hanna Kim8, and for the CARRA Registry Investigators, 1UCSF, San Francisco, CA, 2Duke Clinical Research Institute, Durham, NC, 3Indiana University School of Medicine, Indianapolis, IN, 4Duke University School of Medicine, Durham, NC, 5Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, 6IWK Health Centre, Halifax, NS, Canada, 7University of California, San Francisco, CA, 8National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: While remission off medication is the goal in JDM, timely achievement of clinically inactive disease (CID) is an important interim outcome.  Data from the…
  • Abstract Number: 0804 • ACR Convergence 2024

    Serologic and Clinical Predictors of Progressive Pulmonary Fibrosis in Rheumatoid Arthritis-associated Interstitial Lung Disease Progression: A Prospective Longitudinal Cohort

    Sung Hae Chang1, Misti Paudel2, Gregory McDermott3, Qianru Zhang4, You-Jung Ha5, Jeong Seok Lee6, Min Uk Kim7, Chan Ho Park8, Ji-Won Kim9, Jang Woo Ha10, Sang Wan Chung11, Sung Won Lee12, Eun Ha Kang5, Yeon-Ah Lee13, Jung-Yoon Choe14, Yong-Beom Park15, Eun Young Lee16 and Jeffrey Sparks17, and the KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) group, 1Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, 2Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 3Brigham and Women's Hospital, Brookline, MA, 4Harvard medical school, Cambridge, MA, 5Seoul National University Bundang Hospital, Seongnam, South Korea, 6Korea Advanced Institute of Science and Technology, KAIST,, Daejeon, Republic of Korea, 7SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, 8Soonchunhyang University College of Medicine,, Cheonan-si, Republic of Korea, 9Daegu Catholic University School of Medicine, Nam-gu, Daegu, South Korea, 10Yonsei university college of medicine, Seodaemun-gu, Seoul, South Korea, 11Kyung Hee University Hospital, Seoul, Republic of Korea, 12Soonchunhyang University Cheonan Hospital, Seoul, South Korea, 13Kyung Hee University Hospital, Seoul, South Korea, 14Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, 15Yonsei University College of Medicine, Seoul, Republic of Korea, 163Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 17Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: Predictors of progressive pulmonary fibrosis (PPF) in patients with rheumatoid arthritis-associated interstitial lung disease (ILD) are unclear but may be due to inflammation or…
  • Abstract Number: 2231 • ACR Convergence 2024

    Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort

    Susan Bartlett1, Orit Schieir2, Marie-France Valois1, Louis Bessette3, Janet Pope4, Gilles Boire5, Carol Hitchon6, Ed Keystone7, Carter Thorne8, Diane Tin8, Glen Hazlewood9, Hugues Allard-Chamard10, Bindee Kuriya11, Vivian Bykerk12 and Clifton Bingham13, and Investigators with the Canadian Early Arthritis Cohort (CATCH), 1Centre for Outcomes Research & Eval, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada, 3University of Laval, Quebec City, QC, Canada, 4University of Western Ontario, London, ON, Canada, 5Retired, Sherbrooke, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8Newmarket Rheumatology Consultants, Newmarket, ON, Canada, 9University of Calgary, Calgary, AB, Canada, 10University of Sherbrooke, Sherbrooke, QC, Canada, 11University of Toronto - Toronto, Toronto, ON, Canada, 12Hospital for Special Surgery, New York, NY, 13Johns Hopkins University, Baltimore, MD

    Background/Purpose: Growing evidence suggests that across chronic diseases, patients with co-occurring symptoms of pain, anxiety, and depression (PAD), known as “symptom clusters”, experience variable disease…
  • Abstract Number: 2644 • ACR Convergence 2024

    Baseline Fibroblast Immunophenotype Predicts Clinical Improvement Among Individuals with Early Diffuse Cutaneous Systemic Sclerosis

    Kimberly Lakin1, Robert Spiera2, John Spivack1, Yaxia Zhang1, Jessica Gordon3 and dana Orange4, 1Hospital for Special Surgery, New York, NY, 2Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 3Division of Rheumatology, Weill Cornell Medical College, New York, NY, 4Rockefeller University, New York, NY

    Background/Purpose: We have previously shown that fibroblast CD34 is low and alpha-smooth muscle actin (aSMA) is high in severe diffuse cutaneous systemic sclerosis (dcSSc) skin,…
  • Abstract Number: 0814 • ACR Convergence 2024

    Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension

    Junyan Qian1, Xinzhuang Yang2, Yu Fang Ding3, qian wang1, Jiuliang Zhao1, Weida Liu4, Yongtai Liu5, Zhuang Tian5, Yanhong Wang6, Xiaojian Wang7, Mengtao Li1 and Xiaofeng Zeng8, 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, 2Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine & Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, BEIJING, China (People's Republic), 4State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 5Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, 6Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 7State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, 8Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: Systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH) displays significant clinical heterogeneity; nevertheless, the underlying mechanisms remain unclear. Presently, more than twenty risk genes…
  • Abstract Number: 2247 • ACR Convergence 2024

    Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis

    Klára Prajzlerová1, Olga Kryštufková2, Petra Hánová1, Nora Růžičková2, Hana Hulejová1, Jiří Vencovský2, Ladislav Šenolt2 and Mária Filková2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Autoantibodies, e.g., against citrullinated proteins (ACPA), increase the risk of clinical arthritis and can be detected years before rheumatoid arthritis (RA) onset. EULAR's definition…
  • Abstract Number: 2665 • ACR Convergence 2024

    Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis

    Tsuneo Sasai1, Ran Nakashima1, Atsubumi Ogawa2, Motohiro Nonaka2, Norimichi Nomura2, Yasuhiro Nohda2, Mirei Shirakashi3, Ryosuke Hiwa2, Hideaki Tsuji1, Shuji Akizuki4, Hajime Yoshifuji1, Tsuneyo Mimori5 and Akio Morinobu6, 1Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Kyoto University, Kyoto, Japan, 3Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, 4Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, 5Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, 6Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan

    Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD), leading to poor prognosis. Initial combinational therapy…
  • 1
  • 2
  • 3
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology